2025-01-26 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Summary:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its innovative medicines and vaccines.  Over the period analyzed, MRK's cumulative return (57.74%) significantly underperformed the S&P 500 (VOO) (122.16%). The difference is -64.4%, placing it at the 0th percentile of its historical performance relative to the S&P 500.  The provided Alpha values consistently show negative performance relative to the market benchmark (S&P 500), suggesting underperformance even when accounting for market risk. Beta values are significantly higher than 1, indicating high sensitivity to market fluctuations.

**2. Recent Price Movement:**

* **Closing Price:** $95.55
* **5-Day Moving Average:** $96.40
* **20-Day Moving Average:** $98.92
* **60-Day Moving Average:** $99.66

The stock price is currently below all three moving averages, suggesting a bearish short-term trend. The recent price drop of -$1.12 (from $96.63) reinforces this downward trend.


**3. Technical Indicators & Expected Return:**

* **RSI (37.8):**  Indicates the stock is in oversold territory, potentially suggesting a bounce.
* **PPO (-0.43):** Negative PPO suggests bearish momentum.
* **20-Day Relative Divergence (-12.2%):** Shows a recent downward trend in relative performance.

The substantial negative change in price (-$1.12) indicates a recent downward shift. The projected long-term (2+ years) expected return of 687.6% relative to the S&P 500, however, seems exceptionally high and requires further justification or clarification of the calculation method used to arrive at this number.  This figure should be viewed with significant skepticism.

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in EPS and revenue.  There's a notable drop in EPS from Q2 2024 ($2.15) to Q3 2024 ($1.25).  While revenue generally increased during this period, the inconsistent EPS figures warrant further investigation. The duplicate entry for 2024-11-06 needs clarification.  A more detailed analysis would require access to the full financial statements and further context.


| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2024-11-06 | $1.25 | $16.66B       |
| 2024-08-05 | $2.15 | $16.11B       |
| 2024-05-03 | $1.88 | $15.78B       |
| 2023-11-03 | $1.87 | $15.96B       |
| 2024-11-06 | $1.87 | $15.96B       | *(Duplicate Entry - Needs Clarification)*


**5. Financial Information:**

The financial data reveals a generally healthy revenue growth, but profit margin has shown a slight downward trend from a peak in Q1 2024. The ROE is also volatile, showing significant swings between quarters, indicating potential issues with profitability and efficiency in capital utilization.  Further investigation into the underlying drivers of these fluctuations is necessary.


| Quarter    | Revenue    | Profit Margin | Equity    | ROE    |
|------------|------------|---------------|-----------|--------|
| 2024-09-30 | $16.66B    | 75.51%        | $44.50B   | 7.09%  |
| 2024-06-30 | $16.11B    | 76.76%        | $43.58B   | 12.52% |
| 2024-03-31 | $15.78B    | 77.56%        | $40.36B   | 11.80% |
| 2023-12-31 | $14.63B    | 73.26%        | $37.58B   | -3.26% |
| 2023-09-30 | $15.96B    | 73.29%        | $41.25B   | 11.50% |


**7. Overall Analysis:**

MRK's performance has lagged behind the S&P 500 significantly. While the RSI suggests potential short-term upside, the negative PPO and moving average indicators point to a bearish short-term trend. Recent earnings show some volatility, and the financial data reveals inconsistencies in profitability and return on equity. The extremely high projected long-term expected return warrants extreme caution and should be critically evaluated.  A more in-depth fundamental analysis, including examination of the company's pipeline, competitive landscape, and macroeconomic factors, is needed to form a complete investment opinion.  The data provided is insufficient for making a definitive investment recommendation.  Consider consulting with a financial advisor before making any investment decisions.
